About Glucagon receptor
Glucagon receptor (GCGR) is a protein
from Homo sapiens identified by UniProt accession
P47871, 477 residues long.
MolForge cross-references it against 0 known binders and
230 disease associations.
Target properties
| Protein name | Glucagon receptor |
| UniProt accession | P47871 |
| Gene | GCGR |
| Organism | Homo sapiens |
| Length | 477 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (2)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (230)
Diseases linked to this target (Open Targets).
- GCGR-related hyperglucagonemia · score 0.65
- type 1 diabetes mellitus · score 0.58
- diabetes mellitus · score 0.58
- Hypoglycemia · score 0.56
- infertility · score 0.37
- congenital isolated hyperinsulinism · score 0.34
- obesity · score 0.29
- hemoglobin measurement · score 0.28
- erythrocyte count · score 0.27
- hematocrit · score 0.24
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P47871-F1 | alphafold | PREDICTED | 81.90 | — |
Amino-acid sequence (477 residues)
MPPCQPQRPL LLLLLLLACQ PQVPSAQVMD FLFEKWKLYG DQCHHNLSLL PPPTELVCNR TFDKYSCWPD TPANTTANIS CPWYLPWHHK VQHRFVFKRC GPDGQWVRGP RGQPWRDASQ CQMDGEEIEV QKEVAKMYSS FQVMYTVGYS LSLGALLLAL AILGGLSKLH CTRNAIHANL FASFVLKASS VLVIDGLLRT RYSQKIGDDL SVSTWLSDGA VAGCRVAAVF MQYGIVANYC WLLVEGLYLH NLLGLATLPE RSFFSLYLGI GWGAPMLFVV PWAVVKCLFE NVQCWTSNDN MGFWWILRFP VFLAILINFF IFVRIVQLLV AKLRARQMHH TDYKFRLAKS TLTLIPLLGV HEVVFAFVTD EHAQGTLRSA KLFFDLFLSS FQGLLVAVLY CFLNKEVQSE LRRRWHRWRL GKVLWEERNT SNHRASSSPG HGPPSKELQF GRGGGSQDSS AETPLAGGLP RLAESPF
Explore Glucagon receptor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets